

## Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'

The 5-year follow-up data of the Care-RA cohort are interesting.<sup>1</sup> However, a few points merit consideration and clarification.

Findings in the high-risk group reaffirm the fact that upfront combination disease-modifying antirheumatic drugs (DMARDs) are not needed even in patients of rheumatoid arthritis (RA) with poor prognostic factors, provided a treat-to-target strategy is followed. However, we wish to draw attention to the low-risk group which compared initial methotrexate (MTX) monotherapy to MTX+prednisolone bridging (COBRA-Slim). The results in the low-risk group seem counterintuitive to previous landmark trials (including the BeSt and the TEAR) that found long-term outcomes to be essentially determined by treating-to-target, with the intensity of initial treatment only guiding the rapidity of response achieved.<sup>2,3</sup> However, in the CareRA-plus, the initial difference in disease activity between MTX monotherapy vs MTX+prednisolone bridging (COBRA-Slim) in the low-risk group persisted for up to 5 years—this could reignite interest in the concept of 'a time-limited window of opportunity' in early RA.<sup>4</sup>

However, it must be stressed that any conclusions in the low-risk group should be guarded, as the numbers included in this group (n=49 at the start of this long-term extension study; 38 by the end of follow-up at 5 years) were too few to draw any reliable conclusions. Unfortunately, there was no MTX monotherapy arm in the high-risk group which had more patients, and thus could have better answered the question whether addition of bridging glucocorticoids to initial MTX monotherapy improves long-term outcomes in early RA, when followed by a tight step-up approach to treatment target.

Considering the little incremental response in any treatment arm after the first year, more details regarding the treatment escalation strategies followed after the protocol-specified two step escalation (step 1 and step 2) would be insightful. We would be interested in knowing the treatment changes (switches or additions) after the protocolised first year till year 5 (in the ~50% of patients who required such changes) and the final treatment patients were taking at the end of 5 years.

Nevertheless, the authors must be congratulated for their study which has reaffirmed the fact that excellent results are possible with conventional synthetic DMARDs+prednisolone in

a majority of cases and biological DMARDs are required in only a minority of patients (one-fourth) with RA.

**Siddharth Jain, Varun Dhir** 

Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India

**Correspondence to** Dr Varun Dhir, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India; varundhir@gmail.com

**Contributors** SJ drafted the manuscript. VD critically reviewed and modified it. Both authors approved the final submitted version of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Jain S, Dhir V. *Ann Rheum Dis* 2023;**82**:e162.

Received 22 May 2021

Accepted 25 May 2021

Published Online First 30 June 2021



► <http://dx.doi.org/10.1136/annrheumdis-2021-220857>

*Ann Rheum Dis* 2023;**82**:e162. doi:10.1136/annrheumdis-2021-220816

**ORCID iD**

Varun Dhir <http://orcid.org/0000-0002-3626-0694>

### REFERENCES

- 1 Stouten V, Westhovens R, Pazmino S. Five-Year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial. *Ann Rheum Dis* 2021;**80**:965–73.
- 2 Markusse IM, Akdemir G, Dirven L, *et al*. Long-Term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment. *Ann Intern Med* 2016;**164**:523–31.
- 3 Moreland LW, O'Dell JR, Paulus HE, *et al*. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. *Arthritis & Rheumatism* 2012;**64**:2824–35.
- 4 Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? *Ann Rheum Dis* 2015;**74**:793–4.